If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
278
results.
Updated on
13/11/2026 [06:58:00]
Results 125 to 150 of 278
Absstract of: US20260345503A1
0000 The present disclosure provides methods for generating and/or purifying secretomes, extracellular vesicles, and fractions thereof, from progenitor cells; and provides compositions containing such generated secretomes, extracellular vesicles, and fractions thereof. The present disclosure further provides methods for analyzing activities, and the functionality and potency, of such secretomes, extracellular vesicles, and fractions thereof. The present disclosure also relates to the therapeutic use of secretomes, extracellular vesicles, and fractions thereof. The present disclosure further relates to good manufacturing practices (GMP)-ready, scalable, culture protocol for the release of clinic-ready secretomes.
Absstract of: WO2026229365A1
The present invention provides inventive double-stranded ribonucleic acids, preferably poly(IC), which are capable of interacting with conjugates comprising linear polyethyleneimine fragments, polyethylene glycol fragments and targeting fragments forming polyplexes. The compositions and polyplexes provided herein are useful as therapeutics, in particular as cancer therapeutics.
Absstract of: WO2026227435A1
The present invention belongs to the technical field of biomedicine. Disclosed are a fluorine-modified polysarcosinylated lipid, and a preparation method therefor and the use thereof. The fluorine-modified polysarcosinylated lipid of the present invention has a general structure as represented by formula (I) or formula (II). The fluorine-modified polysarcosinylated lipid obtained by means of chemical modification of a polysarcosinylated lipid with various fluorine-containing groups can replace a PEGylated lipid in the preparation of lipid nanoparticles (LNPs) for loading drugs such as nucleic acids, thereby improving the drug delivery performance.
Absstract of: US20260345510A1
0000 Provided herein are lipid nanoparticle complex with nanoparticles cloaked in monocyte plasma membrane for effective delivery of drugs. Also provided herein are drug loaded lipid nanoparticle complex for inhibition of YAP/TAZ pathway and methods of using the lipid nanoparticles for treatment of atherosclerosis in a subject in need thereof.
Absstract of: US20260345835A1
0000 The present invention relates to cell permeant particles. In particular, the present invention relates to plasma-treated particles or plasma-synthesised particles that are capable of migrating across the membranes of live cells.
Absstract of: US20260345490A1
The present invention relates to a novel composition for the development of stable artificial oxygen carriers based on perfluorocarbons, their preparation and their use as synthetic blood and oxygen replacement carriers and volume substitutes.
Absstract of: US20260345507A1
The present invention relates to lipid nanoparticle (LNP) compositions, and therapeutic polynucleotides, e.g. TERT mRNA, which may be delivered with the LNP compositions in formulations for the prevention or treatment of lung disease and/or fibrosis.
Absstract of: US20260345471A1
0000 An object of the present invention is to provide a novel ingredient for improving various conditions in living organisms, such as sagging skin. An antioxidant of the present invention is characterized by containing extracellular vesicles derived from a dragon fruit. A fibroblast promoter of the present invention is characterized by containing extracellular vesicles derived from a dragon fruit. The dragon fruit is, for example, a red-fleshed dragon fruit.
Absstract of: WO2026227715A1
The present invention provides a schisandrin B-loaded nanovesicle and a functional hydrogel, preparation methods therefor, and use thereof. The present invention belongs to the technical field of medical dressings. In the present invention, human umbilical cord mesenchymal stem cells and schisandrin B are co-mixed, and then gradient extrusion is performed by means of a microporous filter membrane to obtain the schisandrin B-loaded nanovesicle. The engineered stem cell-derived nanovesicle prepared by the present invention can accelerate angiogenesis and promote hepatocyte proliferation, thereby promoting post-hepatectomy injury repair. As a novel visceral wound dressing, the functional hydrogel provided by the present invention not only has good biocompatibility, but also can adsorb blood cells and activate a coagulation cascade system so as to achieve a hemostatic effect.
Absstract of: US20260345767A1
The present disclosure relates to the field of vaccines and binding molecules, as well as preparations and methods of their use in the treatment and/or prevention of disease. Described are vaccines and binding molecules, compositions containing the same, and uses thereof for treating or preventing coronavirus infections, including multivalent miRNA and nanoparticle vaccines.
Absstract of: US20260345509A1
Provided are a donepezil sustained-release microsphere, a preparation method therefor, a pharmaceutical preparation thereof, and use thereof. The preparation method includes the following steps: forming an aqueous phase (including a surfactant, an osmotic pressure regulator, and water, and adjusting a pH value with a pH regulator); forming an oil phase (including donepezil, a carrier material, and an organic solvent); adding the oil phase to the aqueous phase for dispersion to form a pre-emulsion, then carrying out membrane emulsification on the pre-emulsion to form an emulsion; and finally curing, washing, and lyophilizing the emulsion to obtain the donepezil sustained-release microsphere. The preparation process is stable and controllable, with good batch-to-batch repeatability. The microspheres have a smooth and intact surface, uniform particle size distribution and controllable particle size, and possess high drug loading capacity. The microspheres enable long-term and sustained drug release, and exhibit excellent injectability, so that an administration frequency can be reduced, and adverse gastrointestinal reactions can be alleviated.
Absstract of: US20260345506A1
0000 The present disclosure provides a metal-chelated phospholipid complex, a metal-chelated phospholipid complex nanoparticle and a drug-lipid particle, and preparation methods and uses thereof, which relate to the field of biotechnology. The metal-chelated phospholipid complex is formed by reaction of a phospholipid molecular moiety, a linker molecular moiety, and a metal ion moiety. The metal-chelated phospholipid complex nanoparticle comprises a metal-chelated phospholipid complex, a particle aggregation-inhibiting conjugated lipid, and a non-cationic lipid or a non-ionizable lipid. The drug-lipid particle comprises a drug and the metal-chelated phospholipid complex nanoparticle. The metal-chelated phospholipid complex has a function in adsorbing drugs with negative charges and self-assembling with other lipids into metal-chelated phospholipid complex nanoparticles (MPP), so as to avoid the use of cationic lipid or ionizable lipid under the condition of ensuring the effectiveness which is not less than that of LNP, so that the toxicity of the drug-lipid particle is greatly reduced.
Absstract of: US20260345508A1
A specific silicon compound is represented by the following formula:wherein each symbol is as defined in the specification. A composition comprises the silicon compound and cetylpyridinium chloride hydrate and is in the form of nanoparticles. The composition can be easily attached to or carried by a medical material or a medical device in a favorable manner.
Absstract of: US20260347842A1
The present invention provides an interfering RNA targeting microtubule protein β2 (TUBB2). The interfering RNA can reduce the expression of TUBB2, thereby treating a disease related to the increase of TUBB2 expression or excessive proliferation of cells. The present invention further provides a lipid nanoparticle drug comprising the interfering RNA. The lipid nanoparticle drug is used for treating a disease related to the increase of TUBB2 expression or excessive proliferation of cells. The present invention further provides an antibody-nucleic acid conjugate drug, which comprises the interfering RNA and an antibody and is used for treating a disease related to the increase of TUBB2 expression or excessive proliferation of cells.
Absstract of: AU2026254062A1
Ionizable cationic lipids, methods for synthesizing them, as well as intermediates useful in synthesis of these lipids and methods of synthesizing the intermediates are disclosed. The ionizable cationic lipids are useful as a component of lipid nanoparticles (LNP), which in turn can be used for the delivery of nucleic acids into cells in vivo or ex vivo. LNP compositions are also disclosed, including LNP comprising a functionalized lipid to enable conjugation of a binding moiety, and targeted LNP (tLNP), that is a LNP in which a binding moiety has been conjugated to the functionalized lipid and can serve as a targeting moiety to direct the tLNP to a desired tissue or cell type. ct c t
Absstract of: AU2026254002A1
The present invention provides, among other things, a novel class of cationic lipid compounds (e.g., cationic lipids having a structure according to Formula (I)) for in vivo delivery of therapeutic agents, such as nucleic acids. It is contemplated that these compounds are capable of highly effective in vivo delivery while maintaining a favorable toxicity profile. Formula (I) Ho R¹B R¹A OH N b Z a N N a A Ho R¹B R¹A ct c t b a a o ¹
Absstract of: US20260345815A1
A nanoparticle and/or microparticle construct for therapeutic applications includes a plurality of targeting moieties that bind to target molecules of a cell, tissue, and/or disease site in a subject, phosphatidylserine phospholipids, and releasable cloaking agents configured to mask the phosphatidylserine phospholipids prior to binding of the target moieties to the target molecules and be released from the construct to expose the phosphatidylserine phospholipids upon binding of the target moieties to the target molecules.
Absstract of: US20260345660A1
The invention relates generally to tRNA-based effector molecules having a non-naturally occurring modification and methods relating thereto.
Absstract of: US20260345807A1
Treatment and/or diagnosis of a cancer type characterized by expressing zinc transporter ZIP4. The present invention is directed to nanocarriers functionalized with a ligand capable to bind to the extracellular domain of zinc transporter ZIP4, for use in the treatment and/or diagnosis of a cancer type characterized by expressing ZIP4.
Absstract of: US20260345511A1
The present invention provides an improved lipid nanoparticle formulation encapsulating mRNA comprising DEPE as a helper lipid.
Absstract of: US20260345741A1
0000 The present invention provides a pharmaceutical composition comprising an exosome encapsulating one or more cargo RNAs comprising a package RNA and one or more fusion proteins wherein the nucleotide sequence of the package RNA is at least about 80%, about 85%, about 90%, about 95% or about 100% identical to the nucleotide sequence of an elastin (ELN) gene or an elastin messenger RNA (mRNA) that also includes any isoforms. The present invention also provides a method of treatment of elastin deficient related illness in a subject using the pharmaceutical composition of the present invention.
Absstract of: WO2025085759A1
Provided herein is a composition comprising a telomerase or a functional fragment thereof, and/or a telomerase activator, wherein the composition further comprises components for a gene editing system. Also provided are methods of increasing the efficiency of gene editing and methods of editing a gene in a subject.
Absstract of: WO2025085800A1
The present disclosure provides compositions and methods for enhancing gene editing. In some aspects, the compositions and methods are used prevent the progression or treat diseases such as osteoarthritis and other joint disorders that are characterized by an inflammatory component.
Absstract of: AU2026253874A1
The present invention provides compositions comprising peptide-coupled biodegradable poly(lactide-co-glycolide) (PLG) particles. In particular, PLG particles are surface- functionalized to allow for coupling of peptide molecules to the surface of the particles (e.g., for use in eliciting induction of immunological tolerance). ct c t
Nº publicación: US20260345482A1 05/11/2026
Applicant:
ALCON INC [CH]
Alcon Inc.
Absstract of: US20260345482A1
Hydrogel contact lenses for release of active agents can include a hydrogel polymeric matrix having dispersed therein nanohydrogels loaded with active agent. The nanohydrogels can be responsive to pH and be composed of a copolymer prepared from one or more hydrophilic vinylic monomers, and one or more vinylic crosslinkers and/or vinylic crosslinker agents that include carboxylic acids and ether linkages.
BOPI
Electronic site
